Meimarakis G, Spelsberg F, Angele M, Preissler G, Fertmann J, Crispin A, Reu S, Kalaitzis N, Stemmler M, Giessen C, Heinemann V, Stintzing S, Hatz R, Winter H
Department of General, Visceral, Transplantation, Vascular, Trauma, Hand and Plastic Surgery, University of Munich - Grosshadern, Marchioninistrasse 15, 81377, Munich, Germany.
Ann Surg Oncol. 2014 Aug;21(8):2563-72. doi: 10.1245/s10434-014-3646-1. Epub 2014 Mar 26.
The purpose of the present study was to determine differences in prognostic factors for survival of patients with pulmonary metastases resected in curative intent from colon or rectum cancer.
Between 1980 and 2006, prognostic factors after resection of pulmonary metastases in 171 patients with primary rectum or colon tumor were evaluated. Survival of patients after surgical metastasectomy was compared with that of patients receiving standard chemotherapy by matched-pair analysis.
Median survival after pulmonary resection was 35.2 months (confidence interval 27.3-43.2). One-, 3-, and 5-year survival for patients following R0 resection was 88.8, 52.1, and 32.9 % respectively. Complete metastasectomy (R0), UICC stage of the primary tumor, pleural infiltration, and hilar or mediastinal lymph node metastases are independent prognostic factors for survival. Matched-pair analysis confirmed that pulmonary metastasectomy significantly improved survival. Although no difference in survival for patients with pulmonary metastases from lower rectal compared to upper rectal or colon cancer was observed, factors to predict survival are different for patients with lower and middle rectal cancer (R0, mediastinal and/or hilar lymph nodes, gender, UICC stage) compared with patients with upper rectal or colon cancer (R0, number of metastases).
Our results indicate that distinct prognostic factors exist for patients with pulmonary metastases from lower rectal compared with upper rectal or colon cancer. This supports the notion that colorectal cancer should not be considered as a single-tumor entity. Metastasectomy, especially after complete resection resulted in a dramatic improvement of survival compared with patients treated with chemotherapy alone.
本研究的目的是确定根治性切除结肠或直肠癌肺转移患者生存预后因素的差异。
评估1980年至2006年间171例原发性直肠或结肠肿瘤患者肺转移切除术后的预后因素。通过配对分析比较手术切除转移灶后患者的生存率与接受标准化化疗患者的生存率。
肺切除术后的中位生存期为35.2个月(置信区间27.3 - 43.2)。R0切除术后患者的1年、3年和5年生存率分别为88.8%、52.1%和32.9%。完整的转移灶切除术(R0)、原发性肿瘤的国际抗癌联盟(UICC)分期、胸膜浸润以及肺门或纵隔淋巴结转移是生存的独立预后因素。配对分析证实肺转移灶切除术显著提高了生存率。尽管未观察到低位直肠癌肺转移患者与高位直肠癌或结肠癌肺转移患者在生存率上的差异,但低位和中位直肠癌患者(R0、纵隔和/或肺门淋巴结、性别、UICC分期)与高位直肠癌或结肠癌患者(R0、转移灶数量)的生存预测因素不同。
我们的结果表明,低位直肠癌肺转移患者与高位直肠癌或结肠癌肺转移患者存在不同的预后因素。这支持了不应将结直肠癌视为单一肿瘤实体的观点。与单纯接受化疗的患者相比,转移灶切除术,尤其是完整切除后,可显著提高生存率。